SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc.verified

SWTX

Price:

$44.84

Market Cap:

$3.32B

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advance...[Read more]

Industry

Biotechnology

IPO Date

2019-09-13

Stock Exchange

NASDAQ

Ticker

SWTX

The PE Ratio as of May 2024 (TTM) for SpringWorks Therapeutics, Inc. (SWTX) is -8.71

According to SpringWorks Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.71. This represents a change of 29.21% compared to the average of -6.74 of the last 4 quarters.

SpringWorks Therapeutics, Inc. (SWTX) Historical PE Ratio (quarterly & annually)

How has SWTX PE Ratio performed in the past?

The mean historical PE Ratio of SpringWorks Therapeutics, Inc. over the last ten years is -22.70. The current -8.71 PE Ratio has changed 3.74% with respect to the historical average. Over the past ten years (40 quarters), SWTX's PE Ratio was at its highest in in the December 2020 quarter at 76.10. The PE Ratio was at its lowest in in the March 2021 quarter at -29.78.

Quarterly (TTM)
Annual

Average

-22.70

Median

-17.35

Minimum

-70.97

Maximum

0

SpringWorks Therapeutics, Inc. (SWTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of SpringWorks Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 134.78%

Maximum Annual PE Ratio = 0

Minimum Annual Increase = -Infinity%

Minimum Annual PE Ratio = -70.97

Quarterly (TTM)
Annual
YearPE RatioChange
2023-7.0940.18%
2022-5.06-70.87%
2021-17.35-75.55%
2020-70.97134.78%
2019-30.237.20%
2018-28.20-Infinity%

SpringWorks Therapeutics, Inc. (SWTX) Average PE Ratio

How has SWTX PE Ratio performed in the past?

The current PE Ratio of SpringWorks Therapeutics, Inc. (SWTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-9.83

5-year avg

-26.14

10-year avg

-22.70

SpringWorks Therapeutics, Inc. (SWTX) PE Ratio vs. Peers

How is SWTX’s PE Ratio compared to its peers?

SpringWorks Therapeutics, Inc.’s PE Ratio is less than Relay Therapeutics, Inc. (-2.64), less than Stoke Therapeutics, Inc. (-5.92), less than Pliant Therapeutics, Inc. (-5.38), less than Black Diamond Therapeutics, Inc. (-3.16), less than Arvinas, Inc. (-6.60), less than Day One Biopharmaceuticals, Inc. (-6.71), less than Mirati Therapeutics, Inc. (-5.32), less than Amylyx Pharmaceuticals, Inc. (-1.75), less than Terns Pharmaceuticals, Inc. (-4.82), greater than Apellis Pharmaceuticals, Inc. (-12.17), less than TCR2 Therapeutics Inc. (-0.44), greater than Revolution Medicines, Inc. (-13.41), less than Atreca, Inc. (-0.04), less than Passage Bio, Inc. (-0.88), greater than Cerevel Therapeutics Holdings, Inc. (-16.60), greater than Avidity Biosciences, Inc. (-11.25), greater than Blueprint Medicines Corporation (-22.42), less than Sana Biotechnology, Inc. (-6.15), greater than Kymera Therapeutics, Inc. (-16.00), less than Monte Rosa Therapeutics, Inc. (-2.31),

Build a custom stock screener for SpringWorks Therapeutics, Inc. (SWTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SpringWorks Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

SpringWorks Therapeutics, Inc. (SWTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like SpringWorks Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is SpringWorks Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for SpringWorks Therapeutics, Inc. (SWTX)?

What is the highest PE Ratio for SpringWorks Therapeutics, Inc. (SWTX)?

What is the 3-year average PE Ratio for SpringWorks Therapeutics, Inc. (SWTX)?

What is the 5-year average PE Ratio for SpringWorks Therapeutics, Inc. (SWTX)?

How does the current PE Ratio for SpringWorks Therapeutics, Inc. (SWTX) compare to its historical average?